Drugs / TQL1055
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04793620 | Apr → Aug 2021 | pertussis | Adjuvance Technologies, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQL1055 | “Semisynthetic saponin adjuvant TQL1055 administered in combination with an acellular pertussis vaccine.” NCT04793620 ↗ |
| Modality | Other / unclassified | “TQL1055 is a rationally designed, semisynthetic analog of the licensed Quillaja saponin (QS)-21.” NCT04793620 ↗ |